Research ExplorerPublicationsWhy should we care about quality of life in persons with hae...

Why should we care about quality of life in persons with haemophilia?

Standard

Why should we care about quality of life in persons with haemophilia? / Aledort, L; Bullinger, Monika; Mackensen von, Sylvia; Wasserman, J; Young, N L; Globe, D; Group, Health Related Quality Of Life Expert Working Group Of The International Prophylaxis Study.

In: HAEMOPHILIA, Vol. 18, No. 3, 3, 2012, p. 154-157.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Aledort, L, Bullinger, M, Mackensen von, S, Wasserman, J, Young, NL, Globe, D & Group, HRQOLEWGOTIPS 2012, 'Why should we care about quality of life in persons with haemophilia?', HAEMOPHILIA, vol. 18, no. 3, 3, pp. 154-157. <http://www.ncbi.nlm.nih.gov/pubmed/22356125?dopt=Citation>

APA

Aledort, L., Bullinger, M., Mackensen von, S., Wasserman, J., Young, N. L., Globe, D., & Group, H. R. Q. O. L. E. W. G. O. T. I. P. S. (2012). Why should we care about quality of life in persons with haemophilia? HAEMOPHILIA, 18(3), 154-157. [3]. http://www.ncbi.nlm.nih.gov/pubmed/22356125?dopt=Citation

Vancouver

Aledort L, Bullinger M, Mackensen von S, Wasserman J, Young NL, Globe D et al. Why should we care about quality of life in persons with haemophilia? HAEMOPHILIA. 2012;18(3):154-157. 3.

Bibtex

@article{a07dbc6ce2a24f3993beaa5f2c78671f,
title = "Why should we care about quality of life in persons with haemophilia?",
abstract = "The very high cost of haemophilia care, including the increase in use of factor prophylaxis in both children and adults requires that funders of clotting factor concentrates require objective measures of health, such as joint status and quality of life (QOL). Many clinical trials, especially those for licensing of new products, are including QOL instruments in their protocols to evaluate the patients' perspective of wellbeing before and during therapy. This article gives a perspective on QOL the importance of QOL measurement in the field of haemophilia and its impact on patient outcome.",
keywords = "Humans, Health Status Indicators, History, 20th Century, History, 21st Century, History, Ancient, *Quality of Life, Hemophilia A/drug therapy/history/*psychology, Insurance, Health, Reimbursement, Outcome Assessment (Health Care)/history/*methods, Humans, Health Status Indicators, History, 20th Century, History, 21st Century, History, Ancient, *Quality of Life, Hemophilia A/drug therapy/history/*psychology, Insurance, Health, Reimbursement, Outcome Assessment (Health Care)/history/*methods",
author = "L Aledort and Monika Bullinger and {Mackensen von}, Sylvia and J Wasserman and Young, {N L} and D Globe and Group, {Health Related Quality Of Life Expert Working Group Of The International Prophylaxis Study}",
year = "2012",
language = "English",
volume = "18",
pages = "154--157",
journal = "HAEMOPHILIA",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Why should we care about quality of life in persons with haemophilia?

AU - Aledort, L

AU - Bullinger, Monika

AU - Mackensen von, Sylvia

AU - Wasserman, J

AU - Young, N L

AU - Globe, D

AU - Group, Health Related Quality Of Life Expert Working Group Of The International Prophylaxis Study

PY - 2012

Y1 - 2012

N2 - The very high cost of haemophilia care, including the increase in use of factor prophylaxis in both children and adults requires that funders of clotting factor concentrates require objective measures of health, such as joint status and quality of life (QOL). Many clinical trials, especially those for licensing of new products, are including QOL instruments in their protocols to evaluate the patients' perspective of wellbeing before and during therapy. This article gives a perspective on QOL the importance of QOL measurement in the field of haemophilia and its impact on patient outcome.

AB - The very high cost of haemophilia care, including the increase in use of factor prophylaxis in both children and adults requires that funders of clotting factor concentrates require objective measures of health, such as joint status and quality of life (QOL). Many clinical trials, especially those for licensing of new products, are including QOL instruments in their protocols to evaluate the patients' perspective of wellbeing before and during therapy. This article gives a perspective on QOL the importance of QOL measurement in the field of haemophilia and its impact on patient outcome.

KW - Humans

KW - Health Status Indicators

KW - History, 20th Century

KW - History, 21st Century

KW - History, Ancient

KW - Quality of Life

KW - Hemophilia A/drug therapy/history/psychology

KW - Insurance, Health, Reimbursement

KW - Outcome Assessment (Health Care)/history/methods

KW - Humans

KW - Health Status Indicators

KW - History, 20th Century

KW - History, 21st Century

KW - History, Ancient

KW - Quality of Life

KW - Hemophilia A/drug therapy/history/psychology

KW - Insurance, Health, Reimbursement

KW - Outcome Assessment (Health Care)/history/methods

M3 - SCORING: Journal article

VL - 18

SP - 154

EP - 157

JO - HAEMOPHILIA

JF - HAEMOPHILIA

SN - 1351-8216

IS - 3

M1 - 3

ER -